drugset / Trial / NCT00290407
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.
Timeline
- Start
- 2006-03
- Primary completion
- 2010-01
- Completion
- 2010-01
Outcome
Outcome not reported
Stopped (Enrollment): “terminated due to lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |